http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31784904

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 129
issn 0022-3476
pageRange 125-129
publicationName The Journal of Pediatrics
startingPage 125
bibliographicCitation Zembles TN, Bushee GM, Willoughby RE. Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age. The Journal of Pediatrics. 2019 Jun;209():125–9. doi: 10.1016/j.jpeds.2019.02.020.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b5dbf447302c77b40483b6eecf420ae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc5f1aa788613068500c5653473308c7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c39fad5bc50ea6a8af811ccf905fcaa0
date 201906
identifier https://pubmed.ncbi.nlm.nih.gov/30952507
https://doi.org/10.1016/j.jpeds.2019.02.020
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5127
https://portal.issn.org/resource/ISSN/0022-3476
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age
discusses http://id.nlm.nih.gov/mesh/M0001518
http://id.nlm.nih.gov/mesh/M0288015
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000069455Q000627
http://id.nlm.nih.gov/mesh/D018357Q000517
http://id.nlm.nih.gov/mesh/D017410
http://id.nlm.nih.gov/mesh/D000998Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D005865
http://id.nlm.nih.gov/mesh/D010372
http://id.nlm.nih.gov/mesh/D012189
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D012720
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D007231
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000047
http://id.nlm.nih.gov/mesh/D010343Q000706
http://id.nlm.nih.gov/mesh/D007223
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10862
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977

Total number of triples: 38.